logo

FDA Calendar

Share
Company Name Bristol-Myers Squibb Co.
Drug Name Idecabtagene vicleucel (BLA)
Event Name FDA decision on Idecabtagene vicleucel for treatment of adult patients with relapsed and refractory myeloma
Event Date 03/27/2021
Outcome Date
Outcome
Drug Status Priority review
Rival Drugs Janssen’s Darzalex
Market Potential
Other Approvals
News
Return to FDA Calendar